Enveric Biosciences, Inc. products

Every molecule in the Psybrary™ is screened through PsyAITM, a proprietary artificial intelligence (AI) tool. Leveraging AI systems reduces the time and cost of commercial development. It streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these patentable molecules is further screened to see how changes to its makeup alter its effects and whether the new molecule might be used to synthesize additional new molecules. New compounds of sufficient purity undergo pharmacological screening, including non-clinical (receptors/cell lines), pre-clinical (animal) and ultimately clinical (human) evaluations.

Enveric Biosciences seeks to advance novel combinations of CBD with chemotherapeutic agents and immunotherapies. Preclinical data suggests combination therapies may improve the activity of certain chemotherapies or cancer immunotherapies, potentially enabling more potent or longer-lasting therapeutic effects. In addition, combination therapies may allow for the same or greater therapeutic effect with a lower dose of the chemotherapeutic agent, potentially minimizing the severity of side effects.